Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129029 | 0.94 | PDE4A (0.35) | CYP2C9CYP2C19PDE4BPDE4APDE4C | |
| SCHEMBL128765 | 0.94 | CYP2C9 (0.35) | CYP2C9CYP2C19PDE4BPDE4APDE4C | |
| SCHEMBL129075 | 0.91 | PDE4D (0.36) | PDE4BPDE4APDE4CPDE4DKCNH2 | |
| SCHEMBL126614 | 0.90 | GRIN1 (0.36) | PDE4BPDE4APDE4CPDE4DGRIN1 | |
| SCHEMBL130107 | 0.90 | CYP2C9 (0.33) | CYP2C9CYP2C19PDE4BPDE4APDE4C | |
| SCHEMBL128954 | 0.87 | GRIN1 (0.35) | PDE4BPDE4APDE4CPDE4DGRIN1 | |
| SCHEMBL127200 | 0.87 | GRIN1 (0.35) | PDE4BPDE4APDE4CPDE4DGRIN1 | |
| SCHEMBL128908 | 0.87 | PDE4A (0.35) | CYP2C9CYP2C19PDE4BPDE4APDE4C | |
| SCHEMBL129226 | 0.86 | GRIN1 (0.32) | PDE4BPDE4APDE4CPDE4DGRIN1 | |
| SCHEMBL128931 | 0.84 | PDE4A (0.32) | PDE4BPDE4APDE4CPDE4DKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | CYP2C9 96/4885CYP2C19 44/4885PDE4B 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.